New Leaf Venture Partners
New Leaf Venture Partners is a venture capital firm focused on investments in healthcare technology companies.
Business Model:
Revenue: $18M
Employees: 2-10
Rankings
Industries / Tags:
Detailed New Leaf Venture Partners Information
Geographic Data
Address: Times Square Tower , 7 Times Square
City: New York
State: NY
Zip: 10036
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$400M
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies. The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, the venture capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.
Contact Phone:
+16468716400
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2012 | ReShape Lifesciences | Post-IPO Equity | 15M |
| 3/2012 | GluMetrics | Venture Round | 13.3M |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 11/2006 | Concert Pharmaceuticals | Series B | 48.5M |
| 10/2009 | Direct Flow Medical | Series C | 40M |
| 11/2012 | MEI Pharma | Post-IPO Equity | 27.5M |
| 5/2018 | IRLAB Therapeutics | Series A | 15.8M |
| 6/2011 | Aviir | Venture Round | 3M |
| 5/2007 | Interlace Medical | Series B | 3M |
| 7/2008 | Interlace Medical | Series B | 7M |
| 10/2007 | Relypsa | Series A | 33M |
| 4/2013 | Pearl Therapeutics | Venture Round | 41.7M |
| 10/2020 | TigerConnect | Series D | 0 |
| 9/2007 | Pearl Therapeutics | Series A | 15.5M |
| 11/2012 | Pearl Therapeutics | Series D | 65M |
| 6/2015 | Advanced Cell Diagnostics | Series C | 22M |
| 8/2019 | Renovacor | Series A | 11M |
| 5/2016 | AVEO Oncology | Post-IPO Equity | 17M |
| 11/2007 | Oriel Therapeutics | Venture Round | 26.5M |
| 3/2016 | Iterum Therapeutics plc | Series A | 40M |
| 7/2018 | Alector | Series E | 133M |
| 9/2013 | Catalyst Pharmaceuticals Partners | Post-IPO Equity | 15.1M |
| 11/2006 | Aesthetic Sciences | Series A | 6M |
| 8/2020 | Saniona | Post-IPO Equity | 0 |
| 6/2020 | BrightInsight | Series B | 40M |
| 2/2011 | Chimerix | Series F | 45M |
| 5/2016 | Aptinyx | Series A | 0 |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 4/2018 | Rallybio | Series A | 37M |
| 10/2010 | Convergence Pharmaceuticals | Series A | 35.4M |
| 12/2009 | Afferent Pharmaceuticals | Series A | 23M |
| 8/2015 | ReShape Lifesciences | Post-IPO Equity | 38M |
| 9/2019 | BrightInsight | Series A | 25M |
| 6/2016 | Kit Check | Series C | 0 |
| 4/2013 | iRhythm Technologies | Series D | 16M |
| 1/2012 | iRhythm Technologies | Private Equity Round | 12.2M |
| 5/2011 | iRhythm Technologies | Series C | 15M |
| 10/2013 | Versartis | Series D | 0 |
| 7/2010 | Artisan Pharma | Series C | 0 |
| 6/2013 | Kit Check | Series A | 10.4M |
| 1/2012 | Access Closure | Venture Round | 0 |
| 4/2020 | Rallybio | Series B | 0 |
| 2/2007 | Visiogen | Venture Round | 24M |
| 10/2010 | WorldHeart | Venture Round | 25.3M |
| 10/2012 | Access Closure | Venture Round | 0 |
| 6/2012 | Awarepoint | Venture Round | 14M |
| 10/2009 | Neuronetics | Series D | 0 |
| 3/2011 | Synageva BioPharma | Venture Round | 0 |
| 7/2015 | Afferent Pharmaceuticals | Series C | 55M |
| 9/2010 | Intarcia Therapeutics | Debt Financing | 5M |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 6/2007 | BioRelix | Series A | 25.8M |
| 2/2010 | Tioga Pharmaceuticals | Venture Round | 18M |
| 2/2009 | ReShape Medical | Series B | 20M |
| 1/2016 | AiCure | Series A | 12.3M |
| 3/2021 | BrightInsight | Series C | 101M |
| 8/2009 | SchoolCare | Series G | 14.4M |
| 6/2012 | Oxford Immunotec | Equity | 28M |
| 6/2009 | VaxInnate | Series D | 30M |
| 10/2012 | Pearl Therapeutics | Private Equity Round | 23.3M |
| 10/2009 | Synageva BioPharma | Series F | 0 |
| 7/2013 | Karyopharm Therapeutics | Series B | 19M |
| 5/2018 | Neurana Pharmaceuticals | Series A | 0 |
| 9/2006 | Artisan Pharma | Series A | 39M |
| 7/2009 | Presidio Pharmaceuticals | Venture Round | 27M |
| 12/2017 | Aptinyx | Series B | 70M |
| 7/2008 | Pearl Therapeutics | Series A | 18M |
| 4/2014 | Intarcia Therapeutics | Venture Round | 0 |
| 10/2010 | Pearl Therapeutics | Series C | 69M |
| 10/2015 | Arvinas | Series B | 41.6M |
| 1/2006 | Tioga Pharmaceuticals | Series A | 24M |
| 9/2010 | Relypsa | Series B | 70M |
| 8/2015 | Principia Biopharma | Series B | 15.3M |
| 11/2021 | Asimily | Venture Round | 0 |
| 4/2014 | Principia Biopharma | Series B | 50M |
| 7/2012 | Vifor Pharma | Private Equity Round | 0 |
| 4/2013 | Treato | Series B | 14.5M |
| 8/2022 | Arine | Series B | 0 |
| 3/2012 | BioRelix | Venture Round | 2.6M |
| 10/2012 | Relypsa | Venture Round | 2.6M |
| 8/2011 | Relypsa | Series B | 70.1M |
| 9/2011 | CardioKinetix | Series E | 21M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 1/2018 | Braeburn | Debt Financing | 0 |
| 2/2011 | Spine Wave | Series E | 17.5M |
| 6/2015 | Cogent Biosciences | Series B | 65M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 10/2018 | CuraSen Therapeutics | Series A | 54.5M |
| 8/2018 | ReViral | Series B | 0 |
| 2/2010 | Pearl Therapeutics | Series C | 15M |
| 5/2014 | QPID Health | Series B | 12.3M |
| 9/2019 | Passage Bio | Series B | 110M |
| 2/2010 | Intrinsic Therapeutics | Venture Round | 18M |
| 6/2016 | CRISPR Therapeutics | Series B | 0 |
| 10/2007 | Direct Flow Medical | Series B | 27M |
| 9/2015 | Deciphera Pharmaceuticals | Series B | 75M |
| 4/2015 | Dimension Therapeutics | Series B | 65M |
| 11/2012 | Advanced Cell Diagnostics | Series B | 12M |
| 3/2010 | Access Closure | Venture Round | 10M |
| 11/2012 | Intarcia Therapeutics | Venture Round | 160M |
| 11/2015 | ObsEva | Series B | 60M |
| 11/2012 | Intarcia Therapeutics | Debt Financing | 50M |
| 10/2009 | Aviir | Venture Round | 1M |
| 12/2008 | Aviir | Venture Round | 7.8M |
| 6/2013 | Aviir | Series B | 10M |
| 1/2010 | Aviir | Venture Round | 4.2M |
| 6/2010 | Altura Medical | Series A | 20M |
| 2/2011 | Spiracur | Series C | 35M |
| 8/2012 | Vifor Pharma | Series C | 0 |
| 12/2011 | Aviir | Venture Round | 10M |
| 9/2007 | Aviir | Series B | 11.3M |
| 4/2008 | IlluminOss Medical | Series B | 11M |
| 8/2007 | ReShape Lifesciences | Series A | 3M |
| 3/2010 | Aureon Laboratories | Series C | - |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 1/2008 | Sopherion Therapeutics | Venture Round | 0 |
| 3/2007 | ProteoGenix | Series B | 20M |
| 1/2014 | TigerConnect | Series B | 23M |
| 9/2012 | Karus Therapeutics | Series B | 7.6M |
| 10/2012 | Principia Biopharma | Series A | 12.5M |
| 10/2006 | VaxInnate | Series C | 40M |
| 6/2016 | Bluesight | Series C | 20.4M |
| 1/2015 | Bluesight | Series B | 12M |
| 3/2013 | CardioKinetix | Series E | 23M |
| 9/2017 | Truveris | Series D | 25M |
| 4/2018 | Arvinas | Series C | 55M |
| 9/2012 | IlluminOss Medical | Series C | 0 |
| 3/2008 | Spiration | Series G | 18.5M |
| 12/2018 | Bellus Health | Post-IPO Equity | 26M |
| 5/2017 | Harpoon Therapeutics | Series B | 45M |
| 7/2009 | Interlace Medical | Series C | 20.5M |
| 5/2011 | Neuronetics | Series E | 30M |
| 4/2015 | Neuronetics | Series F | 0 |
| 3/2007 | Intarcia Therapeutics | Venture Round | 50M |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 4/2010 | Aureon Laboratories | Series D | 7M |
| 6/2017 | Neuronetics | Series G | 0 |
| 4/2008 | Stromedix | Series B | 25M |
| 7/2013 | Versartis | Series C | 0 |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 4/2006 | Spiration | Series F | 13.4M |
| 8/2008 | GluMetrics | Series C | 20.1M |
| 4/2012 | Direct Flow Medical | Venture Round | 0 |
| 4/2008 | Concert Pharmaceuticals | Series C | 0 |
| 8/2015 | Wave Life Sciences | Series B | 66M |
| 2/2009 | ReShape Lifesciences | Post-IPO Equity | 20M |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 6/2009 | Spiracur | Series B | 20.3M |
| 1/2013 | Versartis | Series C | 0 |
| 4/2018 | Kyruus | Corporate Round | 0 |
| 9/2015 | Kyruus | Series C | 25M |
| 11/2019 | AiCure | Series C | 24.5M |
| 5/2021 | Akili Interactive Labs | Series D | 0 |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 1/2013 | GluMetrics | Debt Financing | 5.6M |
| 7/2020 | Glympse Bio | Series B | 46.7M |
| 11/2018 | Harpoon Therapeutics | Series C | 70M |
| 11/2017 | AiCure | Series B | 15M |
| 10/2012 | Presidio Pharmaceuticals | Venture Round | 8M |
| 8/2008 | ProteoGenix | Series B | 8M |
| 12/2014 | CardioKinetix | Series F | 0 |
| 2/2013 | Aviir | Series B | 10M |
| 2/2014 | Versartis | Series E | 55M |
| 8/2006 | Interlace Medical | Series A | 750k |
| 5/2010 | Oxford Immunotec | Series D | 26M |
| 3/2018 | Technology Will Save Us | Series A | 0 |
| 2/2011 | Versartis | Series B | 21M |
| 4/2015 | Edge Therapeutics | Series C | 56M |
| 2/2012 | Truveris | Series B | 10M |
| 6/2013 | Bluesight | Series A | 10.4M |
| 5/2009 | Visiogen | Series D | 40M |
| 6/2021 | Cleerly | Series B | 0 |
| 6/2017 | Deciphera Pharmaceuticals | Series C | 52M |
| 8/2019 | Qlaris Bio | Series A | 8.2M |
| 8/2020 | ReViral | Series C | 0 |
| 9/2019 | Edgewise Therapeutics | Series B | 50M |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 11/2021 | Asimily | Venture Round | 0 |
| 8/2021 | Dice Therapeutics | Series C | 0 |
| 6/2021 | Cleerly | Series B | 0 |
| 5/2021 | Akili Interactive Labs | Series D | 0 |
| 3/2021 | BrightInsight | Series C | 0 |
| 1/2021 | Dice Therapeutics | Series C | 0 |
| 10/2020 | TigerConnect | Series D | 0 |
| 8/2020 | ReViral | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
